{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.1","upperLimit":"76.3","value":"64.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"9-month overall survival is the percentage of participants remaining alive 9 months from registration.","dispersionType":"90% Confidence Interval","groups":[{"description":"Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).\n\nTreatment directed based on tumor biopsy results requires classification of patients into 1 of 4 potential cohorts: O\\^6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status (negative versus positive) and epidermal growth factor receptor (EGFR) overexpression status (negative versus positive).","id":"OG000","title":"All Patients Starting Assigned Chemoradiation"}],"paramType":"NUMBER","populationDescription":"The analysis population is comprised of the subset of participants who underwent biopsy, obtained a molecularly-based treatment assignment and started assigned chemoradiation therapy.","reportingStatus":"POSTED","timeFrame":"9 months","title":"9-month Overall Survival (OS) Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}